Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 631 to 645 of 1112 results for criteria

  1. Reslizumab for treating severe eosinophilic asthma (TA479)

    Evidence-based recommendations on reslizumab (Cinqaero) for treating severe eosinophilic asthma in adults.

  2. Sotagliflozin with insulin for treating type 1 diabetes (TA622)

    Evidence-based recommendations on sotagliflozin with insulin for treating type 1 diabetes in adults with a body mass index (BMI) of at least 27 kg/m2 , when insulin alone does not provide adequate glycaemic control despite optimal insulin therapy.

  3. The Arrow OnControl powered bone marrow biopsy system for bone marrow aspiration and biopsy (MIB19)

    NICE has developed a Medtech Innovation Briefing (MIB) on the ARROW OnControl powered bone marrow biopsy system for bone marrow aspiration and biopsy

  4. Psychosis and schizophrenia in children and young people: recognition and management (CG155)

    This guideline covers recognising and managing psychosis and schizophrenia in children and young people. It aims to improve early recognition of psychosis and schizophrenia so that children and young people can be offered the treatment and care they need to live with the condition.

  5. Telbivudine for the treatment of chronic hepatitis B (TA154)

    Evidence-based recommendations on telbivudine (Sebivo) for treating chronic hepatitis B in adults.

  6. Microinvasive subconjunctival insertion of a trans-scleral gelatin stent for primary open-angle glaucoma (IPG612)

    Evidence-based recommendations on microinvasive subconjunctival insertion of a trans-scleral gelatin stent for primary open-angle glaucoma in adults. This involves putting a tiny gelatin tube (stent) under the skin at the base of the eye to create a new drainage channel for excess fluid.

  7. Nerve transfer to partially restore upper limb function in tetraplegia (IPG610)

    Evidence-based recommendations on nerve transfer to partially restore upper limb function in people with tetraplegia. This involves connecting an undamaged, functioning, but non-essential nerve near the injury to the damaged essential nerve.

  8. Photodynamic therapy for brain tumours (IPG290)

    Evidence-based recommendations on photodynamic therapy for brain tumours. This involves giving the patient a drug that makes the tissue sensitive to light and then activating it with a laser light source to destroy the tumour cells.

  9. Implanted vagus nerve stimulation for treatment-resistant depression (IPG679)

    Evidence-based recommendations on vagus nerve stimulation for treatment-resistant depression in adults. This involves implanting an electrical stimulator under the skin of the chest and connecting it by wires to the vagus nerve.

  10. The RhinoChill intranasal cooling system for reducing temperature after cardiac arrest (MIB4)

    NICE has developed a Medtech Innovation Briefing (MIB) on the RhinoChill intranasal cooling system

  11. Ruxolitinib for treating polycythaemia vera (TA921)

    Evidence-based recommendations on ruxolitinib (Jakavi) for polycythaemia vera in adults.

  12. Encorafenib plus cetuximab for previously treated BRAF V600E mutation-positive metastatic colorectal cancer (TA668)

    Evidence-based recommendations on encorafenib (Braftovi) plus cetuximab (Erbitux) for treating BRAF V600E mutation-positive metastatic colorectal cancer in adults who have had previous systemic treatment.

  13. Daratumumab in combination for untreated multiple myeloma when a stem cell transplant is suitable (TA763)

    Evidence-based recommendations on daratumumab (Darzalex) with bortezomib, thalidomide and dexamethasone for untreated multiple myeloma when a stem cell transplant is suitable.

  14. Talazoparib for treating HER2-negative advanced breast cancer with germline BRCA mutations (TA952)

    Evidence-based recommendations on talazoparib (Talzenna) for HER2-negative, locally advanced or metastatic breast cancer with germline BRCA1 or BRCA2 mutations in adults.

  15. Brentuximab vedotin for treating relapsed or refractory systemic anaplastic large cell lymphoma (TA478)

    Evidence-based recommendations on brentuximab vedotin (Adcetris) for treating relapsed or refractory systemic anaplastic large cell lymphoma in adults.